Sheets Smith Wealth Management Reduces Position in IQVIA Holdings Inc. $IQV

Sheets Smith Wealth Management trimmed its position in IQVIA Holdings Inc. (NYSE:IQV) by 16.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 38,194 shares of the medical research company’s stock after selling 7,367 shares during the period. Sheets Smith Wealth Management’s holdings in IQVIA were worth $6,514,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Ameliora Wealth Management Ltd. acquired a new position in shares of IQVIA in the fourth quarter valued at about $25,000. International Assets Investment Management LLC purchased a new stake in IQVIA in the fourth quarter valued at approximately $27,000. Gilpin Wealth Management LLC acquired a new position in IQVIA in the 4th quarter worth approximately $27,000. CrossGen Wealth LLC purchased a new position in IQVIA during the 4th quarter worth approximately $28,000. Finally, Measured Wealth Private Client Group LLC purchased a new position in IQVIA during the 3rd quarter worth approximately $30,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Up 0.2%

IQV stock opened at $168.14 on Friday. The company’s 50-day simple moving average is $173.63 and its 200-day simple moving average is $191.68. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a 52-week low of $153.01 and a 52-week high of $247.04. The firm has a market cap of $28.06 billion, a P/E ratio of 20.84, a PEG ratio of 1.44 and a beta of 1.21.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The company had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.IQVIA’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, equities analysts forecast that IQVIA Holdings Inc. will post 11.6 EPS for the current fiscal year.

IQVIA announced that its Board of Directors has approved a stock repurchase program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s board believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Barclays upgraded shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective on the stock in a research note on Friday, March 6th. HSBC set a $210.00 price target on shares of IQVIA in a report on Wednesday, June 3rd. Evercore reissued an “outperform” rating and issued a $185.00 price objective on shares of IQVIA in a report on Wednesday, April 8th. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a report on Sunday, June 14th. Finally, TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and lifted their price target for the company from $174.00 to $213.00 in a research report on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $222.56.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.